Celebrating one year of progress: Reflecting on our journey in advancing clinical sciences

As I mark my first year as Editor-in-Chief of the Journal of Clinical Sciences, I am filled with gratitude and pride in the accomplishments we have achieved together. This past year has been a journey of discovery, innovation, and growth, and I am deeply honored to have overseen a publication that consistently brings valuable contributions to the global medical community. Our mission to advance clinical knowledge, improve patient care, and foster innovation has been at the forefront of every issue. It has been a year of transformative research. The first quarter (January 2024–March 2024) focused on innovating health care with technology and precision. We dived into the intersection of technology and health care. The CerviTech mobile application, designed to address forward head posture caused by smartphone addiction, stood out as a perfect example of how mHealth solutions can revolutionize patient care.[1] This study highlighted the growing problem of musculoskeletal issues tied to smartphone use. The study by Ahmed et al. on onychomycosis illuminated the rising threat of fungal infections, particularly nondermatophyte molds.[2] This study detailed the fungal species responsible for nail infections, the need for accurate diagnosis through fungal cultures, and managing these infections, especially in resource-constrained environments. Surgical case reports to educational advancements for medical professionals are part of articles setting the pace for the year. The second quarter (April 2024–June 2024) focused on addressing complexities in health. One of the standout contributions was a protocol designed to explore gene–environment interactions in neurodegenerative disorders in Nigeria.[3] This research aimed to unravel the environmental and genetic factors contributing to diseases such as Alzheimer’s and Parkinson’s, which are increasingly affecting populations globally, including in Africa.[3] There was a case report on desmoid tumors, that elucidated challenges of treating these rare but complex abdominal tumors in low-resource settings.[4] The third quarter (July 2024–September 2024) showcased innovation in cancer treatment and surgical excellence. The third quarter saw critical advances in cancer research and surgical innovation. Ayandipo et al. delivered a thorough investigation into the treatment outcomes of patients with triple-negative breast cancer (TNBC), a particularly aggressive form of cancer.[5] This study emphasized the need for early detection and targeted therapies, especially in African populations where TNBC is highly prevalent. It marked an important contribution to global cancer research and treatment strategies. In one of the articles, the safety and efficacy of laparoscopic cholecystectomy in Somalia were explored, offering promising results in low-resource settings.[6] The viability of laparoscopic procedures even in environments with limited medical infrastructure was reinforced. In this fourth quarter (October 2024–December 2024), further interesting research and clinical insights are published. We continue to anticipate articles that will push the boundaries of medical knowledge and provide solutions to emerging healthcare challenges as we move forward. Reflecting on a year of growth and impact, the impact factor of the journal improved from 0.1 to 0.2. As we celebrate one year of growth, I am immensely proud of what we have achieved together. To our authors, reviewers, editorial board, and readers, thank you for your commitment to advancing clinical sciences. Your expertise, dedication, and passion have made this journal a cornerstone of medical research and practice, and I am excited for what we will continue to accomplish in the years to come. Together, we are shaping the future of health care.